MUC16 and ovarian carcinoma: The identification percentage elevated to roughly 85–94 percent for individuals with ovarian cancer at stage II-IV, making CA125 a helpful marker solely for detecting late stages of ovarian cancer, which limited the biomarker’s purpose.